Meiji Seika Pharma Files Japan Lawsuit Over Kostaive Misinformation

Mysterious Twist In Vaccine Saga

The Japanese pharma firm has sued a politician claiming defamatory actions on social media around its novel COVID-19 vaccine.

Meiji Seika Pharma filed a defamation lawsuit on Kostaive, revealing a strange finding about a mysterious bestseller. (Shutterstock)

A misinformation dispute in Japan over Arcturus Therapeutics' COVID-19 vaccine Kostaive (ARCT-154) saw an unprecedented twist in December, when local distributor Meiji Seika Pharma decided to pursue a lawsuit and internal investigation over an Amazon bestseller book.

More from Japan

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Eisai Expands Dementia Ecosystem Via EcoNaviSta Acquisition

 
• By 

Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.

Multiple Factors Behind Accelerating Private Equity Plays In Japan, APAC

 

With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.

Novartis Joins MRGPRX2 Race Through $800m+ Kyorin Deal

 
• By 

Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.

More from Therapy Areas

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow

 

After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage

 

J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.